{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:53:14Z","timestamp":1783021994639,"version":"3.54.6"},"reference-count":60,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Korea government (MSIT)","award":["RS-2024-00347600"],"award-info":[{"award-number":["RS-2024-00347600"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Deucravacitinib, a selective oral tyrosine kinase 2 (TYK2) inhibitor, has demonstrated strong efficacy in the treatment of moderate-to-severe psoriasis. It works through an allosteric mechanism to selectively inhibit TYK2, leading to the suppression of the IL-23\/Th17\/IL-17 axis and a reduction in key pro-inflammatory cytokines such as IL-17A, IL-17F, IL-22, and IL-23. This review focuses on the clinical implications of deucravacitinib in East Asian patients, highlighting its efficacy, safety, and differences in treatment outcomes compared to other populations. Data from pivotal trials such as POETYK PSO-3 and PSO-4, which included East Asian populations, demonstrated robust efficacy and safety profiles, often surpassing results observed in global trials like POETYK PSO-1 and PSO-2. Subgroup analyses and network meta-analyses further corroborate these findings, providing a comprehensive understanding of its therapeutic potential in this demographic. Factors such as lower body mass index, genetic predispositions, and environmental influences may contribute to these differences in response. The safety profile of deucravacitinib is favorable, with low rates of serious adverse events and stable laboratory parameters. This review underscores the need for further research to investigate the genetic, metabolic, and environmental factors that may influence treatment outcomes, aiming to optimize personalized treatment strategies for East Asian patients with psoriasis.<\/jats:p>","DOI":"10.3390\/jcm14051746","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T05:54:38Z","timestamp":1741154078000},"page":"1746","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Exploring the Efficacy, Safety, and Clinical Implications of Deucravacitinib in East Asians with Psoriasis: A Narrative Review"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6246-0331","authenticated-orcid":false,"given":"Chul-Hwan","family":"Bang","sequence":"first","affiliation":[{"name":"Department of Dermatology, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3099-4109","authenticated-orcid":false,"given":"Chul-Jong","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Bucheon St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 14647, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon-Seob","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Bucheon St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 14647, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/1346-8138.17132","article-title":"Epidemiological analysis of the patients with psoriasis in Asian countries and region using the same clinical case cards between 2020 and 2022","volume":"51","author":"Tokuyama","year":"2024","journal-title":"J. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2147\/PTT.S288345","article-title":"Updates on the Treatment of Erythrodermic Psoriasis","volume":"11","author":"Lo","year":"2021","journal-title":"Psoriasis Targets Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000528850","article-title":"Higher Prevalence of Generalized Pustular Psoriasis in Asia? A Population-Based Study Using Claim Data in China and a Systematic Review","volume":"239","author":"Feng","year":"2023","journal-title":"Dermatology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1001\/jamadermatol.2020.3275","article-title":"Association of Clinical and Demographic Factors With the Severity of Palmoplantar Pustulosis","volume":"156","author":"Dand","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/pcmedi\/pbz011","article-title":"Genetics of psoriasis: A basis for precision medicine","volume":"2","author":"Ran","year":"2019","journal-title":"Precis. Clin. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Karampinis, E., Papadopoulou, M.-M., Chaidaki, K., Georgopoulou, K.-E., Magaliou, S., Roussaki Schulze, A.V., Bogdanos, D.P., and Zafiriou, E. (2024). Plaque Psoriasis Exacerbation and COVID-19 Vaccination: Assessing the Characteristics of the Flare and the Exposome Parameters. Vaccines, 12.","DOI":"10.3390\/vaccines12020178"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"32","DOI":"10.5021\/ad.22.110","article-title":"Comparison of Risk Allele Frequencies of Psoriasis-Associated Single-Nucleotide Polymorphisms in Different Population Groups","volume":"35","author":"Lee","year":"2023","journal-title":"Ann. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/PTT.S323281","article-title":"Risk Factors for Psoriasis Flares: A Narrative Review","volume":"14","author":"Potestio","year":"2024","journal-title":"Psoriasis Targets Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris\u2014Part 1: Treatment and monitoring recommendations","volume":"34","author":"Nast","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1007\/s13555-023-01034-7","article-title":"Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis","volume":"13","author":"Armstrong","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1111\/1346-8138.17448","article-title":"Indirect comparison of deucravacitinib and other systemic treatments for moderate to severe plaque psoriasis in Asian populations: A systematic literature review and network meta-analysis","volume":"51","author":"Tsai","year":"2024","journal-title":"J. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"106642","DOI":"10.1016\/j.phrs.2022.106642","article-title":"Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis","volume":"189","author":"Roskoski","year":"2023","journal-title":"Pharmacol. Res."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Jensen, L.T., Attfield, K.E., Feldmann, M., and Fugger, L. (2023). Allosteric TYK2 inhibition: Redefining autoimmune disease therapy beyond JAK1-3 inhibitors. eBioMedicine, 97.","DOI":"10.1016\/j.ebiom.2023.104840"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Zhou, Y., Li, X., Shen, R., Wang, X., Zhang, F., Liu, S., Li, D., Liu, J., Li, P., and Yan, Y. (2022). Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.884399"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.immuni.2006.09.009","article-title":"Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity","volume":"25","author":"Minegishi","year":"2006","journal-title":"Immunity"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s13555-021-00596-8","article-title":"Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1\/2\/3 Inhibitors","volume":"11","author":"Chimalakonda","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"eaaw1736","DOI":"10.1126\/scitranslmed.aaw1736","article-title":"Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain","volume":"11","author":"Burke","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Hoisnard, L., Lebrun-Vignes, B., Maury, S., Mahevas, M., El Karoui, K., Roy, L., Zarour, A., Michel, M., Cohen, J.L., and Amiot, A. (2022). Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-10777-w"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Shawky, A.M., Almalki, F.A., Abdalla, A.N., Abdelazeem, A.H., and Gouda, A.M. (2022). A Comprehensive Overview of Globally Approved JAK Inhibitors. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14051001"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1136\/annrheumdis-2022-eular.1377","article-title":"AB0890 Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials","volume":"81","author":"Warren","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1007\/s13555-024-01224-x","article-title":"Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials","volume":"14","author":"Armstrong","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamadermatol.2024.4688","article-title":"Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years: An Open-Label Extension of Randomized Clinical Trials","volume":"161","author":"Armstrong","year":"2025","journal-title":"JAMA Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/1346-8138.16740","article-title":"Efficacy and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: Subgroup analysis of a randomized, double-blind, placebo-controlled, global phase 3 trial","volume":"50","author":"Imafuku","year":"2023","journal-title":"J. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/bjd\/ljae406","article-title":"Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan, and South Korea with moderate to severe plaque psoriasis: A phase 3 randomized clinical trial","volume":"192","author":"Zhang","year":"2024","journal-title":"Br. J. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/1346-8138.17074","article-title":"Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open-label, phase 3 trial","volume":"51","author":"Imafuku","year":"2024","journal-title":"J. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Hagino, T., Saeki, H., Fujimoto, E., and Kanda, N. (2024). Long-term effectiveness and safety of deucravacitinib in psoriasis: A 52-week real-world study of genital, scalp, and nail lesions. Clin. Exp. Dermatol., llae530.","DOI":"10.1093\/ced\/llae530"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2307489","DOI":"10.1080\/09546634.2024.2307489","article-title":"Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan","volume":"35","author":"Hagino","year":"2024","journal-title":"J. Dermatolog. Treat."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/ced\/llae312","article-title":"Effectiveness of deucravacitinib for genital, nail and scalp lesions in patients with psoriasis: A 24-week real-world study","volume":"50","author":"Hagino","year":"2024","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Hagino, T., Onda, M., Saeki, H., Fujimoto, E., and Kanda, N. (2024). Predictive factors for responders to deucravacitinib treatment in patients with psoriasis. J. Dermatol., online version.","DOI":"10.1111\/1346-8138.17601"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1111\/jdv.19925","article-title":"Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52\u2009weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)","volume":"38","author":"Strober","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_36","unstructured":"(2025, February 25). Available online: https:\/\/news.bms.com\/news\/corporate-financial\/2025\/New-Five-Year-Sotyktu-deucravacitinib-Data-Show-Consistent-Safety-and-Durable-Response-Rates-in-Moderate-to-Severe-Plaque-Psoriasis\/default.aspx."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jaad.2014.02.012","article-title":"Diet and psoriasis, part I: Impact of weight loss interventions","volume":"71","author":"Debbaneh","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Kunz, M., Simon, J.C., and Saalbach, A. (2019). Psoriasis: Obesity and Fatty Acids. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01807"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1038\/nutd.2012.26","article-title":"The association between psoriasis and obesity: A systematic review and meta-analysis of observational studies","volume":"2","author":"Armstrong","year":"2012","journal-title":"Nutr. Diabetes"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"103577","DOI":"10.1016\/j.autrev.2024.103577","article-title":"Global prevalence of obesity in patients with psoriasis: An analysis in the past two decades","volume":"23","author":"Wang","year":"2024","journal-title":"Autoimmun. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Park, S.H., Lee, K.A., Choi, J.H., Park, S., Kim, D.W., and Jung, S.Y. (2023). Impact of Obesity on the IL-6 Immune Marker and Th17 Immune Cells in C57BL\/6 Mice Models with Imiquimod-Induced Psoriasis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065592"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s40261-021-01080-z","article-title":"Impact of Body Mass Index on the Efficacy of Biological Therapies in Patients with Psoriasis: A Real-World Study","volume":"41","author":"Pirro","year":"2021","journal-title":"Clin. Drug Investig."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s13555-024-01123-1","article-title":"Response Types and Factors Associated with Response Types to Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis from Two Randomized Clinical Trials","volume":"14","author":"Egeberg","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/bjd\/ljae147","article-title":"Insulin resistance impairs biologic agent response in moderate-to-severe plaque psoriasis: Insights from a prospective cohort study in China","volume":"191","author":"Huang","year":"2024","journal-title":"Br. J. Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/jdv.18825","article-title":"Brodalumab in plaque psoriasis: Real-world data on effectiveness, safety and clinical predictive factors of initial response and drug survival over a period of 104\u2009weeks","volume":"37","author":"Rompoti","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/1346-8138.15109","article-title":"Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2","volume":"46","author":"Reich","year":"2019","journal-title":"J. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1007\/s13555-024-01268-z","article-title":"A Descriptive, Post Hoc Analysis of Efficacy and Safety of Risankizumab in Diverse Racial and Ethnic Patient Populations with Moderate-to-Severe Psoriasis","volume":"14","author":"Alexis","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1038\/ncomms7916","article-title":"Genome-wide meta-analysis identifies multiple novel associations and ethnic heterogeneity of psoriasis susceptibility","volume":"6","author":"Yin","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jdermsci.2020.05.008","article-title":"The current landscape of psoriasis genetics in 2020","volume":"99","author":"Ogawa","year":"2020","journal-title":"J. Dermatol. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Ren, Y., Wang, L., Dai, H., Qiu, G., Liu, J., Yu, D., Liu, J., Lyu, C.Z., Liu, L., and Zheng, M. (2022). Genome-wide association analysis of anti-TNF-\u03b1 treatment response in Chinese patients with psoriasis. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.968935"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41397-018-0040-6","article-title":"Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis","volume":"18","author":"Massey","year":"2018","journal-title":"Pharmacogenom. J."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Cui, J., Stahl, E.A., Saevarsdottir, S., Miceli, C., Diogo, D., Trynka, G., Raj, T., Mirkov, M.U., Canhao, H., and Ikari, K. (2013). Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet., 9.","DOI":"10.1371\/journal.pgen.1003394"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.foodchem.2009.11.038","article-title":"Antioxidant activity and profiles of common vegetables in Singapore","volume":"120","author":"Isabelle","year":"2010","journal-title":"Food Chem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s42779-019-0002-x","article-title":"Healthy food traditions of Asia: Exploratory case studies from Indonesia, Thailand, Malaysia, and Nepal","volume":"6","author":"Harmayani","year":"2019","journal-title":"J. Ethn. Foods"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"183","DOI":"10.4162\/nrp.2014.8.2.183","article-title":"Total antioxidant capacity of the Korean diet","volume":"8","author":"Han","year":"2014","journal-title":"Nutr. Res. Pract."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/jamadermatol.2023.6236","article-title":"Use of Efficiency Frontiers to Align Prices and Clinical Benefits of Biologic Therapies for Plaque Psoriasis","volume":"160","author":"Egilman","year":"2024","journal-title":"JAMA Dermatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/09546634.2018.1466022","article-title":"Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States","volume":"29","author":"Wu","year":"2018","journal-title":"J. Dermatolog. Treat."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/03007995.2023.2214046","article-title":"Cost per responder of biologic drugs used in the treatment of moderate-to-severe plaque psoriasis in France and Germany","volume":"39","author":"Nyholm","year":"2023","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"adv00215","DOI":"10.2340\/00015555-3569","article-title":"Disease and Treatment Characteristics in Geriatric Psoriasis: A Patient Survey Comparing Age Groups","volume":"100","author":"Groenewoud","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Almenara-Blasco, M., Gracia-Caza\u00f1a, T., Poblador-Plou, B., Laguna-Berna, C., Carmona-P\u00edrez, J., Navarro-Bielsa, A., Prados-Torres, A., Gimeno-Miguel, A., and Gilaberte, Y. (2024). Multimorbidity of Psoriasis: A Large-Scale Population Study of Its Associated Comorbidities. J. Clin. Med., 13.","DOI":"10.3390\/jcm13020492"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/5\/1746\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:47:29Z","timestamp":1760028449000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/5\/1746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":60,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["jcm14051746"],"URL":"https:\/\/doi.org\/10.3390\/jcm14051746","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]}}}